Gold tier: mechanically validated evidence, with its primary source.
117 evidence items · page 3 / 5
7.4 %The frequency of COVID-19 cases was 7.4% (n = 10/135) among febrile patients screened in Gabon from October 2021 to December 2021.
GabonCOVID-19observed October 2021 to December 2021published 2022Southern African journal of infectious diseaseseurope_pmcdocument of 4 observations
91.42 %The seroprevalence of SARS-CoV-2 antibodies in the 40-49 age group in Gabon was 91.42% (95% CI: 88.7–93.5).
GabonCOVID-19observed up to December 2021published 2024Viruseseurope_pmcdocument of 5 observations
1 deathsAmong 92 hospitalized COVID-19 cases at the Regional Hospital of Lambaréné, there was 1 death.
GabonCOVID-19observed 2020published 2022Medecine tropicale et sante internationalePubMeddocument of 6 observations
92 %The seroprevalence of SARS-CoV-2 antibodies in Ogoué-Lolo province, Gabon, was 92%.
GabonCOVID-19observed up to December 2021published 2024SARS-CoV-2 Antibody Seroprevalence in Gabon: Findings from the Nationwide Household Serosueurope_pmcdocument of 6 observations
12 %12% of SARS-CoV-2 infected subjects had chronic diseases.
GabonCOVID-19published 2021Scientific reportseurope_pmcdocument of 23 observations
18 per_1The ratio of seroprevalence from infection to cumulative incidence of confirmed cases ranged from 18:1 to 954:1 in Africa.
GabonCOVID-19published 2022BMJ global healtheurope_pmcdocument of 4 observationsDOI 10.1136/bmjgh-2022-008793
68.3 %Among 837 patients with COVID-19 in Gabon from March to June 2020, 572 (68.3%) were men and 264 (31.5%) were women.
GabonCOVID-19observed March to June 2020published 2021JAMA network openPubMeddocument of 10 observations
The B.1.1.7 variant of SARS-CoV-2 was detected in a hospitalized patient in Gabon in January 2021.
GabonCOVID-19observed January 2021published 2021Journal of medical virologyeurope_pmcdocument of 2 observationsDOI 10.1002/jmv.27164
90 %The seroprevalence of SARS-CoV-2 antibodies in Estuaire province, Gabon, was 90%.
GabonCOVID-19observed up to December 2021published 2024SARS-CoV-2 Antibody Seroprevalence in Gabon: Findings from the Nationwide Household Serosueurope_pmcdocument of 6 observations
2 %2% (N = 11) of SARS-CoV-2 infected persons had dyspnea.
GabonCOVID-19published 2021Scientific reportseurope_pmcdocument of 23 observations
37 yearsThe median and mean ages of SARS-CoV-2 infected subjects were 37 and 38 years respectively.
GabonCOVID-19published 2021Scientific reportseurope_pmcdocument of 23 observations
The B.1.1.7 variant of SARS-CoV-2 was introduced to Gabon in December 2020.
GabonCOVID-19observed December 2020published 2021Journal of medical virologyeurope_pmcdocument of 2 observationsDOI 10.1002/jmv.27164
13,097 patientsA total of 13,097 COVID-19 patients sampled between mid-2021 to early 2022 from 22 African countries were tested for BA.1 by real-time RT-PCR.
GabonBA.1 · COVID-19observed mid-2021 to early 2022published 2022Science (New York, N.Y.)europe_pmcdocument of 5 observations
69 patientsAmong 305 surveyed patients with COVID-19, 69 (23%) had renal insufficiency, which posed a risk of adverse interactions with hydroxychloroquine.
GabonCOVID-19 · renal insufficiencypublished 2021International journal of infectious diseases : IJID : official publication of the InternatPubMeddocument of 8 observations
165 patientsAmong 305 surveyed patients with COVID-19, 165 (54%) had health conditions that did not prohibit but posed a risk of adverse interactions with hydroxychloroquine.
GabonCOVID-19published 2021International journal of infectious diseases : IJID : official publication of the InternatPubMeddocument of 8 observations
36.2 %The overall prevalence of anti-SARS-CoV-2 antibodies was 36.2% among 1492 enrolled people in Gabon.
GabonCOVID-19published 2021BMC Research NotesOpenAlexdocument of 7 observationsDOI 10.1186/s13104-021-05570-3
78.3 %78.3% of COVID-19 patients were positive for anti-SARS-CoV-2 antibodies.
GabonCOVID-19published 2021Scientific reportseurope_pmcdocument of 23 observations
24.5 %Among 809 SARS-CoV-2 samples screened by qRT-PCR in Gabon from March 2020 to September 2021, 198 (24.5%) were classified as VOC Delta (B.1.617.2).
GabonB.1.617.2 · COVID-19 · VOC Deltaobserved March 2020 to September 2021published 2022Frontiers in medicineeurope_pmcdocument of 13 observationsDOI 10.3389/fmed.2022.877391
91.78 %The seroprevalence of SARS-CoV-2 antibodies in the 20–29 age group in Gabon was 91.78% (95% CI: 89.5–93.6).
GabonCOVID-19observed up to December 2021published 2024SARS-CoV-2 Antibody Seroprevalence in Gabon: Findings from the Nationwide Household Serosueurope_pmcdocument of 6 observations
22.3 %After 48 hours of treatment, 50 (22.3%) patients had a significant prolongation of QTc interval.
GabonCOVID-19published 2022Clinics and practiceeurope_pmcdocument of 5 observations
46.1 yearsPatients with severe COVID-19 symptoms had a mean age of 46.1 years (SD 14.7 years), compared to 41.3 years (SD 12.5 years) for those with mild symptoms and 35.7 years (SD 11.3 years) for those with no symptoms.
GabonCOVID-19observed March to June 2020published 2021JAMA network openPubMeddocument of 10 observations
31 %The B.1.1.318 lineage increased by 31% in the Gabonese population between February and May 2021.
GabonB.1.1.318 lineage · COVID-19observed February and May 2021published 2022International journal of infectious diseases : IJID : official publication of the Internateurope_pmcdocument of 2 observationsDOI 10.1016/j.ijid.2021.10.057
2.7 %2.7% (N = 16) of SARS-CoV-2 infected persons had influenza-like symptoms associated with anosmia and ageusia.
GabonCOVID-19published 2021Scientific reportseurope_pmcdocument of 23 observations
58 patientsAmong 305 surveyed patients with COVID-19, 58 (19%) had heart failure, which posed a risk of adverse interactions with hydroxychloroquine.
GabonCOVID-19 · insuffisance cardiaquepublished 2021International journal of infectious diseases : IJID : official publication of the InternatPubMeddocument of 8 observations
39 patientsAmong 305 surveyed patients with COVID-19, 39 (13%) had haematologic/haemato-oncologic diseases, which prohibited administration of hydroxychloroquine.
GabonCOVID-19 · haematologic/haemato-oncologic diseasespublished 2021International journal of infectious diseases : IJID : official publication of the InternatPubMeddocument of 8 observations
Every row leads to its source document. The figure shown counts the VALIDATED observations it carries, never the extracted ones: the two differ on most documents. The exact source excerpt is not published, due to copyright constraints.